Clinical trials: Adenocarcinoma of the Rectum
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
This phase I/II trial tests the safety, side effects, best dose, and efficacy of FOLFOX and bevacizumab in combination with botensilimab and balstilimab (3B-FOLFOX) in treating patients with microsatellite stable (MSS) colorectal…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT05627635
- Testing
- Balstilimab, Bevacizumab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Rectal Cancer Stage T1-T2, Rectal Cancer Nodal Metastasis
IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment
ABSTRACT Background The current management on rectal cancer based on TNM staging has some limitations. In early rectal cancer T stage can be not sufficient to predict the nodal status and, in locally advanced rectal cancer after…
- Trial name
- IMMUNOREACT1 (NCT04915326)
- Testing
- rectal resection
- Where
- Italy
- Volunteers
- 466 people
- Sponsor
- University of Padova
Colorectal Cancer, Esophageal Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for gastrointestinal cancer.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00025532
- Testing
- iodine I 131 monoclonal antibody CC49-deltaCH2
- Where
- United States
- Sponsor
- University of California, San Francisco
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases
PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with colorectal cancer and resectable metastases.
- Conditions
- Colorectal Cancer, Metastatic Cancer, Chemotherapy
- Trial name
- MIROX (NCT00268398)
- Testing
- oxaliplatin, folinic acid, fluorouracil, oxaliplatin, irinotecan, folinic acid, fluorouracil
- Where
- 32 sites in France
- Volunteers
- 284 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Locally Advanced Malignant Neoplasm, Rectal Carcinoma
Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
The purpose of this study is to determine whether the tailored management of locally advanced rectal carcinoma can improve the oncologic and functional outcome.
- Trial name
- GRECCAR4 (NCT01333709)
- Testing
- Induction trichemotherapy - FOLFIRINOX regimen, Early tumor response evaluation by MRI volumetry, Radiochemotherapy Cap 50
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Rectal Carcinoma, Laparoscopy
Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer
The study evaluates the feasibility and advantage of modified laparoscopic double-staple anastomosis technique which to eliminate the 'dog ears' in laparoscopic rectal anterior resection.
- Conditions
- Rectal Carcinoma, Laparoscopy, Anastomotic Leak
- Trial name
- NCT02770911
- Testing
- without "Dog Ear" group, with "Dog Ear" group
- Volunteers
- 250 people
- Sponsor
- Fujian Medical University
Colorectal Cancer, Metastatic Cancer
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00936832
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- France
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colon Adenocarcinoma, Rectal Adenocarcinoma
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
This phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous…
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma
- Trial name
- NCT02393755
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Nintedanib
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Rectal Adenocarcinoma
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
- Trial name
- DWI_RECT_MRGRT (NCT03961776)
- Testing
- MRI-guided radiotherapy by on-board DWI sequences
- Where
- 2 sites in United States, France
- Volunteers
- 39 people
- Sponsor
- Institut Paoli-Calmettes
Rectal Adenocarcinoma
A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
This is a phase I study incorporating bavituximab into the care of patients with rectal adenocarcinoma simultaneously treated with capecitabine and radiation therapy.
- Trial name
- NCT01634685
- Testing
- Radiation, Bavituximab, Capecitabine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Locally Advanced Malignant Neoplasm, Rectal Carcinoma
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
Locally advanced rectal carcinoma raise the issue of both the oncological control, local and general, and the therapeutic morbidity.
- Trial name
- GRECCAR14 (NCT04749108)
- Testing
- Induction chemotherapy - modified FOLFIRINOX regimen, Early tumor response evaluation by MRI volumetry, Radiochemotherapy Cap 50
- Where
- 30 sites in France
- Volunteers
- 1,075 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle